Alpharma Announces New Sales and Marketing Leadership in its Pharmaceuticals Business

BRIDGEWATER, N.J., April 9 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company, announced two changes in its Pharmaceuticals sales and marketing organization.

Scott Shively has been appointed to the newly created role of Senior Vice President Sales and Marketing. Scott's most recent assignment was Interim President and Chief Executive Officer of Altana Pharma US, Inc., where he also served as Senior Vice President for Altana's Global Respiratory Franchise. Scott's experience includes the role of Vice President, Marketing at Endo Pharmaceuticals, where he provided marketing leadership in the areas of pain management, supportive care oncology, anesthesiology/critical care and neurology. Scott also was also Vice President of Global Strategy and Commercial Development at Mallinckrodt Inc's Imaging Division, and prior to that had held Vice President of Global Marketing roles at Hoechst Marion Roussel (Aventis).

David Whitehead has joined Alpharma as Vice President of Sales. Dave has extensive sales experience at Bristol-Myers Squibb, including District Sales Manager and Regional Sales Director in various therapeutic areas including cardiovascular, metabolics and neuroscience. He held Vice President level positions in Government Operations, Hospital and Institutional Sales, and Managed Care. Dave's most recent assignment was Vice President, Sales for the Neuroscience Division which had revenues of $1.9 billion and a sales organization of over 700 specialty representatives.

"I am pleased to welcome these two talented and accomplished leaders to our organization," commented Dr. Ronald Warner, President of Alpharma's Pharmaceuticals Division. "These changes are indicative of our commitment to enhance our sales and marketing organization with talented leaders having exceptional track records in support of our current KADIAN(R) product, and also to begin the critical market preparation for the future launch of Alpharma's innovative abuse-deterrent product platform."

Press releases are also available at our website: http://www.alpharma.com/. About Alpharma Inc.

Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded pharmaceuticals franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.